Announced Fri, 24 Jul · 14:57 IST
Laurus Labs Q1 FY27: Revenue up 29%, Net Profit up 126%
Compliance View source PDF
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+9.0%1-day move
₹1570.00
prior close
₹1588.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3+0.9+0.7+1.1+9.0—————————
Up moveDown movePending
AI summary
Laurus Labs reported Q1 FY27 results with revenue of Rs 2,026 Cr, up 29% YoY from Rs 1,570 Cr. EBITDA grew 66% to Rs 644 Cr with margins expanding to 31.8%, up 7 pts. Net Profit surged 126% to Rs 368 Cr; diluted EPS at Rs 6.8. CDMO revenue jumped 67% to Rs 870 Cr led by small molecules; Affordable Medicines grew 10% to Rs 1,156 Cr. R&D spend rose 74% to Rs 118 Cr. In-licensed two ADC assets.
Likely market impact
Record revenue with sharply higher profits, expanding margins, and strong CDMO growth signal robust operational momentum for shareholders.